By TOM MURPHY, Associated Press Health Writer

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Related Articles

US stocks slip as Wall Street sees both good and bad in Big Tech profits, US-China relations

Why your financial planner might tell you to keep the mortgage

China agrees to purchase 25 million metric tons of U.S. soybeans annually, treasury secretary says

Gadgets: MagicMount Flask

Burlington to open new Parkville store, adding dozens of local jobs

Lilly said Thursday that its top-selling drugs, Mounjaro and Zepbound, brought in more than $10 billion combined during the recently completed third quarter. That made up over half of the drugmaker’s $17.6 billion in to

See Full Page